Revolution in allergy research: New test products for children!

Revolution in allergy research: New test products for children!

Deeside, Großbritannien - realhcare has announced the successful production of the first production hinges of milk and egg provocation tests in pharmaceutical quality today. These products are sent internationally to clinics that work on innovative therapeutic approaches to treat food allergies. The company is thus expanding its product portfolio with peanuts, milk and eggs that are used for clinical studies.

The newly developed food provocation tests are tailor -made for the special requirements of food allergief research and clinical facilities. In the United States, 46 % of adults and 40 % of children suffer from food allergies, with many of them suffering from multiple allergies. The tests are suitable for all phases of clinical studies, including double-blind, placebo-controlled oral provocation tests, as used in other allergic reactions, which also include the use of test allergens on the mucous membranes, as often occur in research [ pei.de ].

innovation pipeline and product extensions

The company plans to further expand its innovation pipeline to develop products for the "Top 9" Allergens and specially developed products for children from 6 months. Prototypes with other allergens such as hazelnuts and cashew nuts have already been made.

Production takes place at the Reacta Healthcare location in Deeside, Great Britain, and meets the requirements of the MHRA. All test meals from this production are designed for allergen identification and standardization and are manufactured according to CGMP standards. Since 2017, Reacta Healthcare has submitted documents to various health authorities, including the FDA and the EMA, to register the products and also ensure their safety.

clinical studies and their importance

Clinical research plays an important role in the further development of treatment options for allergies. Clinical studies are controlled scientific studies on examining new therapy methods and medicines. A leading example is the Charité study center, which has been carrying out clinical studies in numerous indications for over 20 years [ iFa.Charite.de ].

The studies carried out there have already contributed to improving the quality of life of patients with allergological diseases. With new therapy approaches, existing treatment options are to be optimized and effective strategies to combat allergies are to be developed. An example of such studies includes the interaction of antihistamines that are used in the treatment of chronic urticaria.

Overall, the development of Reacta Healthcare and the ongoing clinical studies show the clear need for innovative solutions in the field of allergy research and therapy. The path to the effective treatment of allergic reactions is clear and favored by intensive research and cooperation among the various actors in healthcare.